CC
ALT icon

Centiva Capital’s Altimmune ALT Stock Holding History

Centiva Capital’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-124,900
Closed -$483K – 1064
2025
Q2 		$483K Buy
+124,900
New +$676K 0.01% 969

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's ALT Position: Q2 2026 in Review

Centiva Capital opened a new position in Altimmune (ALT) in Q2 2026: 17,938 shares worth $54.5K. The stake represents ﹤0.01% of the portfolio and ranks #1611 among its holdings. This is a return to the name: Centiva Capital previously reported a position in ALT as recently as Q2 2025.

Centiva Capital first reported a position in ALT in Q3 2024 and has held it in 4 quarters since. The position peaked at $357K in Q2 2025. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Centiva Capital held 17,938 shares of Altimmune worth $54.5K as of Q2 2026.
  • Altimmune was a new Centiva Capital position in Q2 2026.
  • Altimmune made up ﹤0.01% of Centiva Capital's portfolio in Q2 2026, its #1611 holding.
  • Centiva Capital first reported a position in Altimmune in Q3 2024 and has held it in 4 quarters since.
  • Centiva Capital's Altimmune position peaked at $357K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.